Liftstream is an executive search recruitment company in the life sciences sector
AM-Pharma raises 12.2m Euros
Authored by James Sheppard
Symphogen’s Monoclonal Antibody Technology Making Waves
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, antibody drug conjugate, clinical trials, conjugated mAb, epidermal growth factor receptor, Essex Woodland, European Society of Hematology, Genentech, hematology, Kirsten Drejer, Medicon Valley, Merck, monoclonal antibody, Novo A/S, oncology, Phase II, PKA, Roche, squamous cell carcinoma of the head & neck, SYM004, Symphogen
Leave a comment
Ablynx and AbbVie sign inflammatory disease agreement
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged AbbVie, Ablynx, ALX-0061, Belgium, clincal trials, Ed Moses, Flanders Biotech, Humira, Luxembourg, Merck Serono, methotrexate, monoclonal antibody, Netherlands, Phase II, rheumatoid arthritis, systemic lupus erythematosus
Leave a comment
Omeros into phase 1 clinical trial in Europe
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged aHUS, Alexion, clinical development, Gregory Demopulos, mannan-binding lectin-associated serine protease-2, MASP-2, Omeros Corporation, Omeros Pharma, OMS721, Phase II, Soliris, thrombotic microangiopathy, uremic syndrome, US Biotech
Leave a comment
Prosensa & GSK pool resources to drive Drisapersen in Duchenne
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged Abingworth, David Mott, DMD, Drisapersen, Duchenne, Dystrophin, Exon 51, Genzyme, GSK, GSK’s Centre of Excellence for External Drug Discovery, Hans Schikan, Henri Termeer, Huntington's, Leiden University Medical Center, Massachusetts, MedImmune, mRNA, New Enterprise Associates (NEA), Phase II, PRO051, Prosensa, The New England Journal of Medicine
Leave a comment